fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

INM

InMed Pharmaceuticals, Inc.

  ( )

Page Views : 41604

Analyst Ratings

 
Buy
Strong Buy
0%
Buy
100%
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

vista's key points

  • InMed is leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids.
  • InMed is the first company to advance the rare cannaboid, cannabinol (CBN) into a clinical trial as a potential therapeutic to treat diseases with unmet needs.
  • InMed has developed strong preclinical and clinical evidence for two lead indications in dermatology and ocular diseases.
  • InMed's lead product, INM-755, is under development for the treatment of epidermolysis bullosa (“EB”), a severe genetic skin disorder, which affects approximately 50,000 patients in North America, Europe, & Japan.
  • InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in EB.
  • InMed's INM-088 product is in preclinical development for the treatment of glaucoma, the second leading cause of blindness in the developed world.
  • InMed's continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach in advance of large-scale production. InMed’s cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields.
  • InMed's IntegraSyn provides a cost effective approach for the manufacturing of rare cannabinoid API’s for the pharmaceutical industry.
  • InMed announced on June 29th that it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.
  • InMed improved their cash position on July 2nd as it closed a private placement with an institutional investor for net proceeds of approximately $11 million

vista's key points

  • InMed is leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids.
  • InMed is the first company to advance the rare cannaboid, cannabinol (CBN) into a clinical trial as a potential therapeutic to treat diseases with unmet needs.
  • InMed has developed strong preclinical and clinical evidence for two lead indications in dermatology and ocular diseases.
  • InMed's lead product, INM-755, is under development for the treatment of epidermolysis bullosa (“EB”), a severe genetic skin disorder, which affects approximately 50,000 patients in North America, Europe, & Japan.
  • InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in EB.
  • InMed's INM-088 product is in preclinical development for the treatment of glaucoma, the second leading cause of blindness in the developed world.
  • InMed's continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach in advance of large-scale production. InMed’s cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields.
  • InMed's IntegraSyn provides a cost effective approach for the manufacturing of rare cannabinoid API’s for the pharmaceutical industry.
  • InMed announced on June 29th that it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.
  • InMed improved their cash position on July 2nd as it closed a private placement with an institutional investor for net proceeds of approximately $11 million

company profile

 

vista's view

InMed Pharmaceuticals is a publicly traded clinical-stage company that trades on the Nasdaq under the symbol INM. InMed is developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (CBN), in diseases with high unmet medical need. The Company is dedicated to delivering new...

Read More

exclusive content

 

Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.

Interviews

    Coming Soon

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Free Email Updates